With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of ...

Novo Nordisk A/S (NYSE:NVO) is one of the Reddit Stocks with the Highest Upside Potential. On August 6, the company stated ...

Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85 th Scientific Sessions in Chicago, US.1 Full ...

PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to ...

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

Novo Nordisk A/S (NYSE:NVO) has made headlines recently by reporting an impressive 18% sales growth in the first half of 2025. This growth highlights the company's significant role in the global ...

In a notable financial update, Novo Nordisk A/S (NYSE:NVO) has reported an impressive 18% sales growth for the first half of 2025. However, this optimistic growth comes with a caveat: the company has ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.

(Reuters) -Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in injection and oral forms during the first quarter of 2026 for ...